Bluejay Diagnostics (BJDX) EPS (Weighted Average and Diluted) (2021 - 2026)

Bluejay Diagnostics has disclosed EPS (Weighted Average and Diluted) across 6 years of filings, most recently posting -$1.95 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$1.95, up 85.51% year-over-year; the trailing twelve-month figure through Mar 2026 was -$15.0 (up 97.12% YoY), and the FY2025 annual result was -$15.25, up 96.66% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$1.95 for Q1 2026 at Bluejay Diagnostics, up from -$10.63 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.1 in Q1 2022 to a low of -$3573.1 in Q4 2023.
• The 5-year median for EPS (Weighted Average and Diluted) is -$10.63 (2025), against an average of -$267.78.
• Across the five-year window, EPS (Weighted Average and Diluted) sank 146719.67% in 2023 and jumped 99.45% in 2025, its largest moves.
• Bluejay Diagnostics' EPS (Weighted Average and Diluted) stood at -$2.43 in 2022, then sank by 146719.67% to -$3573.1 in 2023, then soared by 95.14% to -$173.57 in 2024, then surged by 93.88% to -$10.63 in 2025, then surged by 81.66% to -$1.95 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$1.95 (Q1 2026), -$10.63 (Q4 2025), and -$1.01 (Q3 2025), per Business Quant data.